How long does it take to take targeted drugs for lung cancer to become resistant to them

Hello. , which varies from person to person.

In general.

It's about seven or eight months.

Antimicrobial resistance has developed. It's going to be changed.

This "Liu Ye's Persistence" is still good.

Generally in about half a year.

It's time for a dressing change.

In "Centakang Pharmaceutical Medical".

Qiu Zhaoao's "Detailed Notes on Du Poems": "Du poems have a text that does not accept but is intended to be received, half of which is written in the middle of the title, and half of which is written in the off-topic, such as the four sentences of the poem "Cloud Goes Out" in the poem "White Emperor City", the scene in the rain, and the four sentences of "Returning to Ma Yi", but they write about the situation after the chaos.

In this poem, there are six scenes of thatched cottages, and the next two sigh about the world, and there are interruptions, and the reader should be good. ” 2]

Wu saw Siyun: "Because of the peach tree, I think of the poor, because of the poor and the crow, because of the crow, and because of the crow, I go down with the widows and thieves." ”

Gu Chenyun: "The title belongs to the peach tree, but the meaning is very big. The deeds of the father's life are all in this poem. Take the hall as the view of the world, and take the world as the view of the hall. ”

This depends on the individual, some people even use it for many years, and some people can endure it for a few months and half a year. So it will be updated from generation to generation.

AI helps, you can apply for three generations of free medication.

Can I take targeted drugs for my mother's lung adenocarcinoma in the middle stage.

This depends on the individual, I know that some people have used Inyi for more than 6 years, and some have been resistant for half a year, which one is needed? It doesn't hurt to talk to me!

EGFR (Epidermal Growth Factor Receptor (EGFR) is a member of the receptor tyrosine kinase family, and multiple studies have confirmed that when EGFR binds to ligands, it will cause cascade activation of related signaling pathways in cells, activating downstream pathways, thereby causing the growth, invasion, transformation, angiogenesis and metastasis of tumor cells.

In patients with mutations in exon 19 or 21 of the EGFR tyrosine kinase gene coding region (somatic mutation) in lung cancer cells, the targeted drug gefitinib erlotinib has an efficacy rate of more than 80%.

Unfortunately, tumor targeting** will eventually lead to drug resistance, which is unavoidable, and lung cancer is no exception, which is also one of the biggest problems faced by the medical community.

In other words, if the tumor has been sensitive to targeted drugs, and the drugs have always been effective, it means that the tumor is **, or like hypertension and diabetes, it can be controlled for a long time.

In fact, these are not possible at the moment.

Tumors are mutated from normal cells of the human body, similar to a "living" organism, which is the same as all organisms in the biological world, has a strong ability to adapt to the environment, when the surrounding environment is harmful to it, it will undergo corresponding changes to adapt to the environment, so that the species will not be extinct, similar to the evolution of organisms.

When we use drugs for cancer, most of the sensitive cancer cells will be killed, but there will also be some cancer cells in the process of fighting drugs**, which will change accordingly and become no longer sensitive to drugs, so as to survive, which is the tumorSecondary drug resistance；There are also a small number of tumor cells that are inherently insensitive to the ** drugs used, which means that these drugs are ineffective against these tumor cells, and these cancer cells will also survive, which we call themPrimary drug resistance

The phenomenon of drug resistance in tumors, whether in chemotherapy or in targeting, also exists, and eventually, all sensitive cancer cells are killed, and after the "survival of the fittest", drug-resistant cancer cells will survive tenaciously, and eventually proliferate again in large numbers, make a comeback, and fail.

Tumor drug resistance is the root cause of tumor failure, and if this problem can be solved, the overcoming of cancer is imminent.

In the advanced stage of lung cancer, with the use of targeted drugs, the survival period is greatly prolonged, reaching 6-7 years, or even longer. But, alas, drug resistance will eventually emerge. However, the prolongation of survival has bought time for the emergence of new and more effective drugs.

I started taking Kemena targeted drugs in June last year, and now I am in the hospital again**, because the targeted drugs have failed, and the tumor on my neck is not only bigger, but also has two more! I haven't changed the targeted drug yet, the doctor asked me to inject Lanfene to try, I don't know if it will work, if it doesn't work, I will increase the amount of Kemena, and then I have to change to the third generation of targeted drugs!

There should be, if the drug resistance must be changed, in exchange for such a waste of money, see if you can operate, see one to dig one, and then if the economy is okay, directly on the pd one 1, immunity ** bet.

If you have drug resistance, it won't work, so you can try traditional Chinese medicine conditioning.

Advanced cancer, very simple.

This is due to the fact that the resistance of this targeted drug is relatively strong, and after adapting to taking such a drug, then the body will produce the corresponding antibodies. Even if you develop drug resistance, you should continue to take medicine, so that you can make your body healthier.

This is because targeted drugs can easily produce antibodies. This antibody creates resistance in our body. I don't think it's needed, because it's useless either.

What are the symptoms of drug resistance in patients?

Oral administration of small molecule targeted drugs can develop drug resistance after a certain period of time. For example, non-small cell lung cancer, EGFR mutations will occur when gefitinib is used, but after a period of use, it will develop another gene mutation - T790M mutation, and the efficacy of gefitinib is not good at this time, so osimertinib needs to be used. Therefore, in clinical practice, each patient should choose medication according to his or her actual situation, and the wrong symptomatic medication may not only fail to achieve the best effect, but also produce serious adverse reactions.

We know that lung cancer is divided into small cell lung cancer and non-small cell lung cancer. The targeted drugs we talked about are usually for non-small cell lung cancer, and the targeted drugs are represented by gefitinib, which is often referred to as EGFR-TKI, which is also the first targeted drug for non-small cell lung cancer with the most mature research, for patients with advanced non-small cell lung cancer with **EGFR gene mutations, the median progression-free survival time is 9 to 10 months, and the overall survival time OS is more than two years.

In addition, some targeted drugs also include immune checkpoint inhibitors, anaplastic lymphoma kinase inhibitors, epidermal growth factor inhibitors, Rouwan inhibitors, angiogenesis inhibitors and so on, and the choice of specific drugs depends on the patient's specific gene mutations, and different drugs are used in different clinical trials of different gene mutations, and the time to obtain benefits is also different, so how long can you live with targeted drugs for lung cancer, This depends on the patient's specific gene mutation, disease stage, and medications.

Rumors:

Many anti-tumor targeted drugs will be resistant to drugs after a period of time, so some patients with malignant tumors believe that they cannot continue to take a handful of targeted drugs, and must take drugs intermittently.

Refutation of rumors:

Every targeted drug is entering the clinic.

Use. Before.

All. It is necessary to study the best for a certain tumor through a long period of clinical trials.

Dosing regimen. Includes:

Choose. optimal route of administration and formulation of administration;

Are you sure. optimal dosing interval;

Compute. the optimal dosage to be administered; Observe the efficacy and.

Undesirable. reaction, monitoring of blood drug concentration, safety and efficacy evaluation and dose adjustment. For example.

The targeted drugs gefitinib and icotinib commonly used in spring lesions in lung cancer patients belong to oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TK).

i。Clinical studies have shown that if EGFR-TKI is interrupted for a period of time in the middle of use, even if it is continued to be taken in the future, the final effect will be effective.

Yes. drop, so it is not recommended to take EGFR-TKI halfway through the period. If the patient needs to stop the drug due to special circumstances (such as serious adverse reactions, etc.) during the use of the drug, it is necessary to consult a clinician, follow the doctor's advice, and the time of stopping the drug should not exceed 2 weeks, and then the previous dose needs to be resumed.

Resistance to tumor-targeted drugs.

Mechanism. It is not very clear at the moment, reported.

More main.

Mechanisms include drug transporter overexpression, altered pharmacokinetics, and amplification of drug targets.

It is likely that the combination of multiple drug resistance mechanisms leads to the occurrence of targeted drug resistance, such as the establishment of compensatory signaling pathways, changes in target proteins, changes in tumor microenvironment, tumor heterogeneity, and tumor adaptation to targeted drugs. The mechanism of resistance to targeted drugs is complex.

Only passed. Intermittent admixture.

Not necessarily.

Delay drug resistance.

Purpose, on the contrary, intermittent dosing may also lead to more complex drug resistance mechanisms, bringing greater losses to **.

The intermittent dosing that may occur during targeted drugs** is not a measure to delay drug resistance.

For example, a prospective phase clinical study evaluating the feasibility, safety, and clinical efficacy of sunitinib admitted** in advanced kidney cancer. The results of this clinical trial show that patients with advanced kidney cancer who have not received sunitinib in the past can be appropriately temporarily discontinued when taking sunitinib**, so as to reduce toxicity and improve the quality of life of patients without affecting clinical efficacy. This study demonstrates that it is feasible for patients taking sunitinib** to be stable in the course of taking the drug for a short period of time to alleviate adverse effects.

In conclusion, it is unscientific to delay the resistance of targeted drugs by taking drugs intermittently, and patients should use drugs rationally under the guidance of doctors.

Rumor refutation expert: Liang Ping.

Liu Mingfeng. The Fourth Hospital of Hebei Medical University.

Faculty of Pharmacy. Pharmacist in charge.

Review expert: Liu Jiang.

Chief pharmacist, Department of Pharmacy, Fourth Hospital of Hebei Medical University.